Cargando…

Immune escape and resistance to immunotherapy in mismatch repair deficient tumors

Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients with Lynch Syndrome who inherit an inactive MMR allele have an up to 80% risk for developing a mismatch repair deficient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mestrallet, Guillaume, Brown, Matthew, Bozkus, Cansu Cimen, Bhardwaj, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363668/ https://www.ncbi.nlm.nih.gov/pubmed/37492581 http://dx.doi.org/10.3389/fimmu.2023.1210164

Ejemplares similares

Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
por: Roudko, Vladimir, et al.
Publicado: (2021)

Strategies to overcome DC dysregulation in the tumor microenvironment
por: Mestrallet, Guillaume, et al.
Publicado: (2022)

A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses
por: Cimen Bozkus, Cansu, et al.
Publicado: (2021)

Long-lasting SARS-CoV-2-specific T cell memories
por: Cimen Bozkus, Cansu
Publicado: (2020)

SARS-CoV-2-specific T cells without antibodies
por: Bozkus, Cansu Cimen
Publicado: (2020)

Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors
por: Takahashi, Nobuyuki, et al.
Publicado: (2020)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
por: Auclin, Edouard, et al.
Publicado: (2021)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
por: Pearson, Joshua R. D., et al.
Publicado: (2020)

No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency
por: Tesch, Victoria K., et al.
Publicado: (2018)

Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape
por: Glaire, Mark A, et al.
Publicado: (2022)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
por: Qureshi, Naveen, et al.
Publicado: (2023)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
por: Cheng, Yi-Kan, et al.
Publicado: (2022)

Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
por: Li, Na, et al.
Publicado: (2023)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

Editorial: Tumor-promoting immune cells: Cancer immune escape and beyond
por: Domblides, Charlotte, et al.
Publicado: (2023)

Skin Immunity and Tolerance: Focus on Epidermal Keratinocytes Expressing HLA-G
por: Mestrallet, Guillaume, et al.
Publicado: (2021)

Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
por: Mei, Wei-Jian, et al.
Publicado: (2022)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
por: Chouaib, Salem, et al.
Publicado: (2012)

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
por: Westcott, Peter M. K., et al.
Publicado: (2023)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

DNA Damage Repair in Brain Tumor Immunotherapy
por: Zhao, Shihong, et al.
Publicado: (2022)

Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance
por: Perales-Linares, Renzo, et al.
Publicado: (2023)

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody
por: Zhou, Wenyue, et al.
Publicado: (2021)

A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

C-Type Lectin Receptors in Antiviral Immunity and Viral Escape
por: Bermejo-Jambrina, Marta, et al.
Publicado: (2018)

Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
por: Zhang, Yingyi, et al.
Publicado: (2017)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

TIM-3 as a molecular switch for tumor escape from innate immunity
por: Mattei, Fabrizio, et al.
Publicado: (2013)

Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?
por: Bruttel, Valentin S., et al.
Publicado: (2014)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

Genotype Directed Therapy in Murine Mismatch Repair Deficient Tumors
por: Kucherlapati, Melanie H., et al.
Publicado: (2013)

Mismatch repair deficiency is rare in bone and soft tissue tumors
por: Lam, Suk Wai, et al.
Publicado: (2021)

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
por: Engelsen, Agnete S. T., et al.
Publicado: (2022)

Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment
por: Giannopoulos, Spyridon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1i7voa1rtva5pbdu9ogldji9bi